Allergic Rhinitis - Pipeline Review, H2 2016

Allergic Rhinitis - Pipeline Review, H2 2016


  • Products Id :- GMDHC8463IDB
  • |
  • Pages: 179
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Allergic Rhinitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Allergic Rhinitis - Pipeline Review, H2 2016', provides an overview of the Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis

- The report reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Allergic Rhinitis therapeutics and enlists all their major and minor projects

- The report assesses Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Allergic Rhinitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Allergic Rhinitis Overview 9

Therapeutics Development 10

Pipeline Products for Allergic Rhinitis - Overview 10

Pipeline Products for Allergic Rhinitis - Comparative Analysis 11

Allergic Rhinitis - Therapeutics under Development by Companies 12

Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes 16

Allergic Rhinitis - Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Allergic Rhinitis - Products under Development by Companies 20

Allergic Rhinitis - Products under Investigation by Universities/Institutes 25

Allergic Rhinitis - Companies Involved in Therapeutics Development 26

3M Drug Delivery Systems 26

Accolade Pharmaceuticals, LLC 27

AFFiRiS AG 28

ALK-Abello A/S 29

Allergy Therapeutics Plc 30

Ampio Pharmaceuticals, Inc. 31

Array BioPharma Inc. 32

ASIT biotech s.a. 33

Axikin Pharmaceuticals, Inc. 34

Chong Kun Dang Pharmaceutical Corp. 35

Chrysalis BioTherapeutics, Inc. 36

ELORAC, Inc. 37

Faes Farma, S.A. 38

Fountain Biopharma Inc. 39

GlaxoSmithKline Plc 40

Glenmark Pharmaceuticals Ltd. 41

HAL Allergy BV 42

Hisamitsu Pharmaceutical Co., Inc. 43

Johnson & Johnson 44

Laboratorios LETI S.L. 45

Ligand Pharmaceuticals, Inc. 46

Marinomed Biotechnologie GmbH 47

Merck & Co., Inc. 48

Panmira Pharmaceuticals, LLC. 49

Paradigm Biopharmaceuticals Limited 50

Pfizer Inc. 51

Protectimmun GmbH 52

Roxall Medizin GmbH 53

Sanofi 54

Shionogi & Co., Ltd. 55

Stallergenes Greer plc 56

Sun Pharma Advanced Research Company Ltd. 57

Taiho Pharmaceutical Co., Ltd. 58

VentiRx Pharmaceuticals, Inc. 59

Xencor, Inc. 60

Allergic Rhinitis - Therapeutics Assessment 61

Assessment by Monotherapy Products 61

Assessment by Combination Products 62

Assessment by Target 63

Assessment by Mechanism of Action 65

Assessment by Route of Administration 67

Assessment by Molecule Type 69

Drug Profiles 71

(azelastine hydrochloride + budesonide) - Drug Profile 71

(fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile 72

(levocabastine hydrochloride + mometasone furoate) - Drug Profile 73

854-A - Drug Profile 74

Allergen for Allergic Asthma and Allergic Rhinitis - Drug Profile 75

Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile 76

Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 77

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile 78

Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile 79

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 80

Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 81

Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 82

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 83

Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 84

AM-211 - Drug Profile 85

AM-461 - Drug Profile 86

Ampion - Drug Profile 87

AR-460770 - Drug Profile 95

Arabinogalactan - Drug Profile 96

asapiprant - Drug Profile 97

B-244 - Drug Profile 98

beta-escin - Drug Profile 99

bilastine - Drug Profile 100

budesonide - Drug Profile 102

CBP-174 - Drug Profile 103

cidoxepin hydrochloride - Drug Profile 104

clustoid wiesenlieschgras - Drug Profile 105

desloratadine - Drug Profile 106

emedastine difumarate - Drug Profile 108

esketamine hydrochloride - Drug Profile 109

FB-825 - Drug Profile 112

gp-ASIT - Drug Profile 113

GSK-2245035 - Drug Profile 115

GSP-301 - Drug Profile 117

Lactococcus lactis G121 - Drug Profile 118

motolimod - Drug Profile 119

nasapaque - Drug Profile 122

pentosan polysulfate sodium - Drug Profile 123

PF-06444752 - Drug Profile 125

PF-06444753 - Drug Profile 127

Pollinex Quattro Tree - Drug Profile 129

rE58 - Drug Profile 131

Small Molecule for Allergic Rhinitis - Drug Profile 132

Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile 133

Small Molecule to Antagonize G Protein Coupled Receptors for Respiratory Disorders - Drug Profile 134

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis - Drug Profile 135

Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile 136

STAGR-120 - Drug Profile 137

standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile 138

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 140

SUN-0597 - Drug Profile 145

TAS-205 - Drug Profile 147

Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile 148

VTX-1463 - Drug Profile 149

XmAb-7195 - Drug Profile 150

Zafi-3 - Drug Profile 151

Allergic Rhinitis - Dormant Projects 152

Allergic Rhinitis - Discontinued Products 162

Allergic Rhinitis - Product Development Milestones 165

Featured News & Press Releases 165

Appendix 174

Methodology 174

Coverage 174

Secondary Research 174

Primary Research 174

Expert Panel Validation 174

Contact Us 174

Disclaimer 175

List of Figures

Number of Products under Development for Allergic Rhinitis, H2 2016 15

Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Products, H2 2016 23

Assessment by Monotherapy Products, H2 2016 65

Assessment by Combination Products, H2 2016 66

Number of Products by Top 10 Targets, H2 2016 67

Number of Products by Stage and Top 10 Targets, H2 2016 67

Number of Products by Top 10 Mechanism of Actions, H2 2016 69

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 69

Number of Products by Top 10 Routes of Administration, H2 2016 71

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 71

Number of Products by Molecule Types, H2 2016 73

Number of Products by Stage and Molecule Types, H2 2016 73

List of Tables

Number of Products under Development for Allergic Rhinitis, H2 2016 15

Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Development, H2 2016 23

Products under Development by Companies, H2 2016 24

Products under Development by Companies, H2 2016 (Contd..1) 25

Products under Development by Companies, H2 2016 (Contd..2) 26

Products under Development by Companies, H2 2016 (Contd..3) 27

Products under Development by Companies, H2 2016 (Contd..4) 28

Products under Investigation by Universities/Institutes, H2 2016 29

Allergic Rhinitis - Pipeline by 3M Drug Delivery Systems, H2 2016 30

Allergic Rhinitis - Pipeline by Accolade Pharmaceuticals, LLC, H2 2016 31

Allergic Rhinitis - Pipeline by AFFiRiS AG, H2 2016 32

Allergic Rhinitis - Pipeline by ALK-Abello A/S, H2 2016 33

Allergic Rhinitis - Pipeline by Allergy Therapeutics Plc, H2 2016 34

Allergic Rhinitis - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 35

Allergic Rhinitis - Pipeline by Array BioPharma Inc., H2 2016 36

Allergic Rhinitis - Pipeline by ASIT biotech s.a., H2 2016 37

Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals, Inc., H2 2016 38

Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 39

Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016 40

Allergic Rhinitis - Pipeline by ELORAC, Inc., H2 2016 41

Allergic Rhinitis - Pipeline by Faes Farma, S.A., H2 2016 42

Allergic Rhinitis - Pipeline by Fountain Biopharma Inc., H2 2016 43

Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H2 2016 44

Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 45

Allergic Rhinitis - Pipeline by HAL Allergy BV, H2 2016 46

Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 47

Allergic Rhinitis - Pipeline by Johnson & Johnson, H2 2016 48

Allergic Rhinitis - Pipeline by Laboratorios LETI S.L., H2 2016 49

Allergic Rhinitis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 50

Allergic Rhinitis - Pipeline by Marinomed Biotechnologie GmbH, H2 2016 51

Allergic Rhinitis - Pipeline by Merck & Co., Inc., H2 2016 52

Allergic Rhinitis - Pipeline by Panmira Pharmaceuticals, LLC., H2 2016 53

Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Limited, H2 2016 54

Allergic Rhinitis - Pipeline by Pfizer Inc., H2 2016 55

Allergic Rhinitis - Pipeline by Protectimmun GmbH, H2 2016 56

Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, H2 2016 57

Allergic Rhinitis - Pipeline by Sanofi, H2 2016 58

Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2016 59

Allergic Rhinitis - Pipeline by Stallergenes Greer plc, H2 2016 60

Allergic Rhinitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 61

Allergic Rhinitis - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 62

Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 63

Allergic Rhinitis - Pipeline by Xencor, Inc., H2 2016 64

Assessment by Monotherapy Products, H2 2016 65

Assessment by Combination Products, H2 2016 66

Number of Products by Stage and Target, H2 2016 68

Number of Products by Stage and Mechanism of Action, H2 2016 70

Number of Products by Stage and Route of Administration, H2 2016 72

Number of Products by Stage and Molecule Type, H2 2016 74

Allergic Rhinitis - Dormant Projects, H2 2016 156

Allergic Rhinitis - Dormant Projects (Contd..1), H2 2016 157

Allergic Rhinitis - Dormant Projects (Contd..2), H2 2016 158

Allergic Rhinitis - Dormant Projects (Contd..3), H2 2016 159

Allergic Rhinitis - Dormant Projects (Contd..4), H2 2016 160

Allergic Rhinitis - Dormant Projects (Contd..5), H2 2016 161

Allergic Rhinitis - Dormant Projects (Contd..6), H2 2016 162

Allergic Rhinitis - Dormant Projects (Contd..7), H2 2016 163

Allergic Rhinitis - Dormant Projects (Contd..8), H2 2016 164

Allergic Rhinitis - Dormant Projects (Contd..9), H2 2016 165

Allergic Rhinitis - Discontinued Products, H2 2016 166

Allergic Rhinitis - Discontinued Products (Contd..1), H2 2016 167

Allergic Rhinitis - Discontinued Products (Contd..2), H2 2016 168

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3M Drug Delivery Systems

Accolade Pharmaceuticals, LLC

AFFiRiS AG

ALK-Abello A/S

Allergy Therapeutics Plc

Ampio Pharmaceuticals, Inc.

Array BioPharma Inc.

ASIT biotech s.a.

Axikin Pharmaceuticals, Inc.

Chong Kun Dang Pharmaceutical Corp.

Chrysalis BioTherapeutics, Inc.

ELORAC, Inc.

Faes Farma, S.A.

Fountain Biopharma Inc.

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd.

HAL Allergy BV

Hisamitsu Pharmaceutical Co., Inc.

Johnson & Johnson

Laboratorios LETI S.L.

Ligand Pharmaceuticals, Inc.

Marinomed Biotechnologie GmbH

Merck & Co., Inc.

Panmira Pharmaceuticals, LLC.

Paradigm Biopharmaceuticals Limited

Pfizer Inc.

Protectimmun GmbH

Roxall Medizin GmbH

Sanofi

Shionogi & Co., Ltd.

Stallergenes Greer plc

Sun Pharma Advanced Research Company Ltd.

Taiho Pharmaceutical Co., Ltd.

VentiRx Pharmaceuticals, Inc.

Xencor, Inc.

Allergic Rhinitis Therapeutic Products under Development, Key Players in Allergic Rhinitis Therapeutics, Allergic Rhinitis Pipeline Overview, Allergic Rhinitis Pipeline, Allergic Rhinitis Pipeline Assessment

select a license

Single User License
USD 2000 INR 128960
Site License
USD 4000 INR 257920
Corporate User License
USD 6000 INR 386880

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com